Abstract:
A receiver for a radio broadcast signal, in particular a car radio, and a method for receiving a radio broadcast signal, including a signal decoder for decoding an audio signal contained in the radio broadcast signal in encoded form, and/or for decoding a data signal contained in the radio broadcast signal in encoded form, the signal decoder being operable so that the encoded signal is only decoded, when the signal decoder obtains an external authentication signal, which is received via an external transmission path that is different from the transmission path of the radio broadcast signal.
Abstract:
The digital filter includes a first multiplier (2) receiving an input signal, an adder (3) connected to the first multiplier (2) to receive its output signal, a delay element (6) connected to the adder (3) to receive its output signal, a second multiplier (7) connected between the delay element (6) and a second input of the adder (3) in a feedback branch, a device (16) for supplying either of two values (K1.1, K1.2) of a first multiplier coefficient to the first multiplier (2) and a device (17) for supplying either of two values (K2.1, K2.2) of a second multiplier coefficient to the second multiplier (7). The second one (K2.2) of the two values of the second multiplier coefficient is advantageously 0, while the second one (K1.2) of the first multiplier coefficient values is equal to a quotient of a predetermined first one of the first multiplier coefficient values and a difference between one and a predetermined first one of the second multiplier coefficient values.
Abstract:
In a circuit for deriving at least one quality signal that is dependent on the quality of a received signal, where the received signal is demodulated, a first auxiliary signal which is dependent on the field strength, and a second or further auxiliary signal, are derived from the demodulated signal. The auxiliary signal and the second or further auxiliary signal are combined to derive the quality signal.
Abstract:
In a circuit for suppressing short-lived noise phenomena in a digital audio signal, in particular during a temporary test reception of another transmitter, the audio signal is multiplied by a factor which, prior to the appearance of the noise phenomenon, is brought from a maximum value to a minimum value in accordance with a predetermined time function, and at the end of the noise phenomenon, is returned to a maximum value. The invention has special application to the Radio Data System defined by the European Broadcasting Union, and the testing of "Alternative Frequencies" in that system.
Abstract:
The invention relates to novel compounds of formula I where R1, R2, R3, R4, R5, R6, R7, R8, Q1, Q2 and Q3 are each as defined below. The compounds of formula I have antithrombotic activity and inhibit especially protease-activated receptor 1 (PAR1). The invention further relates to a process for preparing the compound of formula I and to the use thereof as a medicament.
Abstract:
The invention relates to a method for producing an injection valve for liquids, preferably an injection valve for injecting fuel into a combustion chamber of an internal combustion engine. The injection valve has a valve body, with a valve seat which is formed therein, and a valve needle which interacts with the valve seat in order to open and close at least one injection opening. The injection valve is produced by means of the following method steps: producing the valve body from steel, hardening the valve body, annealing a partial region of the valve body at an annealing temperature. The device for carrying out the method according to the invention has an inductive annealing generator which generates a suitable alternating current for operating a coil, in the magnetic field of which coil the valve body can be heated for annealing.
Abstract:
The invention relates to novel compounds of formula I where R1, R2, R3, R4, R5, R9, Ar, Q1, Q2 and Q3 are each as defined below. The compounds of the formula I have antithrombotic activity and inhibit especially protease-activated receptor 1 (PAR1). The invention further relates to a process for preparing the compound of the formula I and to the use thereof as a medicament.
Abstract:
The present invention refers to human EGLN2 variants having at position 58 of the amino acid sequence a serine or a leucine and their use in the prevention or treatment of thromboembolic or coronary heart diseases, in particular stroke, prolonged reversible ischemic neurological deficit (PRIND), transitoric ischemic attack (TIA), myocardial infarction and/or early myocardial infarction.
Abstract:
The invention relates to novel compounds of formula I where R1, R2, R3, R4, R5, R6, R7, R8, Q1, Q2 and Q3 are each as defined below. The compounds of formula I have antithrombotic activity and inhibit especially protease-activated receptor 1 (PAR1). The invention further relates to a process for preparing the compound of formula I and to the use thereof as a medicament.
Abstract:
The present invention refers to the use of the Mst protein or a nucleotide sequence coding for the Mst protein for the treatment of a thromboembolic disorder and to a method of screening a modulator of the Mst protein or the nucleotide sequence coding for the Mst protein.